Holen Sie sich die Stockscreener-App
0.2925
5.98%
-0.0186
Handel nachbörslich:
.29
-0.0025
-0.85%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CARA?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$0.3111
Offen:
$0.3111
24-Stunden-Volumen:
798.18K
Relative Volume:
1.73
Marktkapitalisierung:
$17.06M
Einnahmen:
$20.97M
Nettoeinkommen (Verlust:
$-118.51M
KGV:
-0.142
EPS:
-2.06
Netto-Cashflow:
$-94.45M
1W Leistung:
-14.22%
1M Leistung:
+10.34%
6M Leistung:
-61.01%
1J Leistung:
-73.41%
1-Tages-Spanne:
$0.2902
$0.319
1-Wochen-Bereich:
$0.2902
$0.35
52-Wochen-Spanne:
$0.24
$1.31
Cara Therapeutics Inc Stock (CARA) Company Profile
Firmenname
Cara Therapeutics Inc
Sektor
Branche
Telefon
203-406-3700
Adresse
400 ATLANTIC STREET, SUITE 500, STAMFORD, CT
Vergleichen Sie CARA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| CARA | 0.2925 | 17.06M | 20.97M | -118.51M | -94.45M | -2.06 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Cara Therapeutics Inc Stock (CARA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-03-08 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-03-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-11-01 | Fortgesetzt | Canaccord Genuity | Buy |
| 2021-08-03 | Eingeleitet | JP Morgan | Neutral |
| 2020-04-21 | Bestätigt | H.C. Wainwright | Buy |
| 2019-08-12 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-29 | Bestätigt | Laidlaw | Buy |
| 2019-02-06 | Fortgesetzt | Jefferies | Buy |
| 2019-01-15 | Eingeleitet | BofA/Merrill | Neutral |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-13 | Eingeleitet | Jefferies | Buy |
| 2018-08-08 | Bestätigt | Stifel | Buy |
| 2018-06-28 | Bestätigt | H.C. Wainwright | Buy |
| 2018-03-12 | Fortgesetzt | H.C. Wainwright | Buy |
| 2018-02-12 | Hochstufung | Janney | Neutral → Buy |
| 2018-01-19 | Eingeleitet | Seaport Global Securities | Buy |
| 2017-06-30 | Herabstufung | Janney | Buy → Neutral |
| 2017-06-30 | Bestätigt | Laidlaw | Buy |
| 2017-06-30 | Bestätigt | Stifel | Buy |
| 2017-03-28 | Bestätigt | H.C. Wainwright | Buy |
| 2017-03-28 | Bestätigt | Laidlaw | Buy |
| 2017-03-10 | Bestätigt | Laidlaw | Buy |
| 2016-10-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-08-08 | Bestätigt | Needham | Buy |
Alle ansehen
Cara Therapeutics Inc Aktie (CARA) Neueste Nachrichten
Cara Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Stamford’s Cara Therapeutics continues financial struggles; 10-employee workforce down 91% - Hartford Business Journal
Cara Therapeutics Inc. (CARA) Quarterly 10-Q Report - Quartzy
Cara: Q3 Earnings Snapshot - San Antonio Express-News
Cara Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Rigel to Present at the Jefferies London Healthcare Conference - Quantisnow
CARGO Therapeutics, Inc. (NASDAQ:CRGX) Receives Average Rating of “Buy” from Analysts - Defense World
Cara Therapeutics, Inc. (NASDAQ:CARA) Given Average Rating of “Hold” by Analysts - Defense World
Cara Therapeutics CEO Posner sells shares worth $1,063 - Investing.com India
Cara Therapeutics CEO Posner sells shares worth $1,063 By Investing.com - Investing.com Australia
Cara Operations (TSE:CARA) Stock Price Down 2.4% – Here’s Why - Defense World
Cara Therapeutics, Inc.'s (NASDAQ:CARA) Share Price Is Matching Sentiment Around Its Revenues - Simply Wall St
Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update - Quantisnow
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
CSL Limited Reports 13.5% Stake In Cara Therapeutics - XM
Truist Financial Initiates Coverage on Amentum (NYSE:AMTM) - Defense World
América Móvil (NYSE:AMX) PT Lowered to $20.80 - Defense World
Riskified Ltd. (NYSE:RSKD) Given Consensus Recommendation of “Hold” by Analysts - Defense World
Heritage Global Inc. (NASDAQ:HGBL) Shares Acquired by Dimensional Fund Advisors LP - Defense World
Dimensional Fund Advisors LP Purchases 55,636 Shares of VirTra, Inc. (NASDAQ:VTSI) - Defense World
Renaissance Technologies LLC Reduces Position in Cara Therapeutics, Inc. (NASDAQ:CARA) - Defense World
Opioid Use Disorder (OUD) Market Report 2024: Growth, Trends, Competitive Outlook to 2033 - WhaTech
Europe Pruritus Therapeutics Market Size & Outlook, 2030 - Grand View Research
Financial Health Report: Cara Therapeutics Inc (CARA)’s Ratios Tell a Tale - The Dwinnex
What technical indicators reveal about CARA stock - US Post News
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Quantisnow
Medical Marijuana Market Report 2024Growth, Forecast In The Latest Research - WhaTech
Cannabinoid Derived Pharmaceutical Market Share, Size, Growth and Forecast to 2031 - InsightAce Analytic
Cara Therapeutics (NASDAQ:CARA) Receives New Coverage from Analysts at StockNews.com - Defense World
Market Recap: Cara Therapeutics Inc (CARA)’s Positive Momentum, Closing at 0.31 - The Dwinnex
Cara Therapeutics, Inc. (NASDAQ:CARA) Sees Large Increase in Short Interest - Defense World
Stock Analysts’ New Coverage for September 26th (AINC, AIRI, APTO, BLK, CARA, CBOE, CLLS, CME, CMLS, CTLT) - Defense World
G-Protein Coupled Receptors Market Growth Analysis, Trends, Share, Market Size And Forecast To 2033 - WhaTech
A closer look at Cara Therapeutics Inc (CARA) is warranted - US Post News
WesBanco, Inc. (NASDAQ:WSBC) Receives Consensus Rating of “Hold” from Analysts - Defense World
Pruritus Clinical Trials 2024: FDA Approvals, Medication, - openPR
Ra capital executives buy Bicara Therapeutics shares for $32.99m By Investing.com - Investing.com Canada
Aclaris Therapeutics neutral rating reiterated on phase 2a trial - Investing.com
Federated Hermes Inc. Acquires Shares of 670,468 Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Carmat launches capital increase, stock plummets - Marketscreener.com
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sage Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesSAGE - PR Newswire
Most Promising New Drugs for Hidradenitis Suppurativa, with Raj Chovatiya, MD, PhD - MD Magazine
The time has not yet come to remove your chips from the table: Cara Therapeutics Inc (CARA) - SETE News
Cara Therapeutics Inc (CARA)’s Day in Review: Closing at 0.26, Down by -2.85 - The Dwinnex
CARA’s Stock Market Adventure: -62.18% YTD Growth Amidst Volatility - The InvestChronicle
How to interpret Cara Therapeutics Inc (CARA)’s stock chart patterns - US Post News
Pruritus Therapeutics Market Competition & Segment Analysis – Actavis Plc, Amgen Inc., Bristol-Myers Squibb, Cara Therapeutics, Cipla – Cauverynews - Cauverynews
Metric Deep Dive: Understanding Cara Therapeutics Inc (CARA) Through its Ratios - The Dwinnex
Pruritus Pipeline Analysis 2024: FDA Approvals and Emerging - openPR
Does Cara Therapeutics Inc (CARA) offer a good opportunity for investors? - SETE News
Cara Therapeutics (NASDAQ:CARA) Now Covered by Analysts at StockNews.com - Defense World
Finanzdaten der Cara Therapeutics Inc-Aktie (CARA)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):